Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Two Sigma Investments LP

Two Sigma Investments LP grew its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 166.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 135,084 shares of the company's stock after acquiring an additional 84,375 shares during the period. Two Sigma Investments LP owned about 0.18% of Nurix Therapeutics worth $2,545,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Barclays PLC boosted its holdings in Nurix Therapeutics by 77.9% in the third quarter. Barclays PLC now owns 128,344 shares of the company's stock worth $2,884,000 after acquiring an additional 56,190 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Nurix Therapeutics by 31.1% in the 4th quarter. SG Americas Securities LLC now owns 30,086 shares of the company's stock worth $567,000 after buying an additional 7,141 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Nurix Therapeutics by 21.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 15,020 shares of the company's stock worth $283,000 after purchasing an additional 2,632 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its holdings in Nurix Therapeutics by 42.7% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company's stock valued at $14,869,000 after purchasing an additional 235,971 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in Nurix Therapeutics by 13.5% in the 4th quarter. Rhumbline Advisers now owns 103,233 shares of the company's stock valued at $1,945,000 after buying an additional 12,315 shares in the last quarter.

Nurix Therapeutics Stock Up 0.7%

Shares of NASDAQ:NRIX traded up $0.08 during midday trading on Wednesday, reaching $12.16. The company's stock had a trading volume of 598,238 shares, compared to its average volume of 881,062. The stock has a fifty day moving average of $10.33 and a 200 day moving average of $15.52. The firm has a market capitalization of $927.03 million, a PE ratio of -4.21 and a beta of 2.23. Nurix Therapeutics, Inc. has a twelve month low of $8.18 and a twelve month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. The firm had revenue of $18.45 million for the quarter, compared to analyst estimates of $12.78 million. During the same quarter last year, the firm posted ($0.76) EPS. Sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

NRIX has been the subject of several recent analyst reports. Leerink Partners started coverage on Nurix Therapeutics in a research report on Monday, March 17th. They set a "market perform" rating and a $16.00 target price for the company. Needham & Company LLC reiterated a "buy" rating and set a $27.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, April 29th. Stifel Nicolaus reduced their price target on Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating for the company in a report on Wednesday, April 9th. Leerink Partnrs upgraded shares of Nurix Therapeutics to a "hold" rating in a research note on Monday, March 17th. Finally, Wells Fargo & Company dropped their price target on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat, Nurix Therapeutics has an average rating of "Moderate Buy" and an average target price of $30.44.

Insider Buying and Selling

In other Nurix Therapeutics news, CFO Houte Hans Van sold 6,198 shares of the stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $11.33, for a total transaction of $70,223.34. Following the sale, the chief financial officer now directly owns 33,724 shares in the company, valued at $382,092.92. This represents a 15.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Gwenn Hansen sold 3,377 shares of the firm's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total transaction of $38,835.50. Following the completion of the sale, the insider now owns 61,516 shares in the company, valued at $707,434. The trade was a 5.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,013 shares of company stock worth $137,096. 7.40% of the stock is owned by insiders.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.